| Legacy Nursing And Rehabilitation Of Morgan City | |
| 740 Justa Street, Morgan City, Louisiana 70380 | |
| (985) 384-1726 | |
| Name | Legacy Nursing And Rehabilitation Of Morgan City |
|---|---|
| Location | 740 Justa Street, Morgan City, Louisiana |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 88 |
| Occupancy Rate | 71.48% |
| Medicare ID (CCN) | 195386 |
| Legal Business Name | Morgan City Opco, L.l.c. |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1720060544 |
| Organization Name | PINNACLE HEALTH FACILITIES OF LOUISIANA, LLC |
| Doing Business As | MORGAN CITY HEALTH CARE CENTER |
| Address | 740 Justa St, Morgan City, LA 70380 |
| Phone Number | 985-384-1726 |
News Archive
Novus Therapeutics, Inc., a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, announced receipt of final meeting minutes from the U.S. Food and Drug Administration following a Type C meeting held at the Company's request to discuss its OP-02 development program in otitis media.
Some studies have suggested that the rate of change of prostate-specific antigen (PSA) levels may correspond with prostate cancer survival.
When the Northern Virginia Regional Health Information Organization (NoVaRHIO) goes live with its first major step towards an full scale interoperable eHealth Information Exchange (eHIE) connecting patients and physicians across the region, it will leverage GE Healthcare as a key infrastructure partner.
Genetic testing for a certain mutation in pediatric patients is valuable in determining a cause for unexplained hearing loss, according to a study in the November 2012 issue of Otolaryngology-Head and Neck Surgery.
› Verified 1 days ago
| NPI Number | 1861038051 |
| Organization Name | MORGAN CITY OPCO, L.L.C. |
| Address | 740 Justa St, Morgan City, LA 70380 |
| Phone Number | 985-384-1723 |
News Archive
Novus Therapeutics, Inc., a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, announced receipt of final meeting minutes from the U.S. Food and Drug Administration following a Type C meeting held at the Company's request to discuss its OP-02 development program in otitis media.
Some studies have suggested that the rate of change of prostate-specific antigen (PSA) levels may correspond with prostate cancer survival.
When the Northern Virginia Regional Health Information Organization (NoVaRHIO) goes live with its first major step towards an full scale interoperable eHealth Information Exchange (eHIE) connecting patients and physicians across the region, it will leverage GE Healthcare as a key infrastructure partner.
Genetic testing for a certain mutation in pediatric patients is valuable in determining a cause for unexplained hearing loss, according to a study in the November 2012 issue of Otolaryngology-Head and Neck Surgery.
› Verified 1 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Novus Therapeutics, Inc., a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, announced receipt of final meeting minutes from the U.S. Food and Drug Administration following a Type C meeting held at the Company's request to discuss its OP-02 development program in otitis media.
Some studies have suggested that the rate of change of prostate-specific antigen (PSA) levels may correspond with prostate cancer survival.
When the Northern Virginia Regional Health Information Organization (NoVaRHIO) goes live with its first major step towards an full scale interoperable eHealth Information Exchange (eHIE) connecting patients and physicians across the region, it will leverage GE Healthcare as a key infrastructure partner.
Genetic testing for a certain mutation in pediatric patients is valuable in determining a cause for unexplained hearing loss, according to a study in the November 2012 issue of Otolaryngology-Head and Neck Surgery.
› Verified 1 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $650 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 29.9 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 9.18 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 38.61 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 4.6 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 2.88 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 2.28 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 2.54 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 95.34 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 22.75 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 84.62 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.69 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 30.06 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 29.46 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 17.69 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 92.36 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 74.08 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 70.9 | 82.93 |
News Archive
Novus Therapeutics, Inc., a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, announced receipt of final meeting minutes from the U.S. Food and Drug Administration following a Type C meeting held at the Company's request to discuss its OP-02 development program in otitis media.
Some studies have suggested that the rate of change of prostate-specific antigen (PSA) levels may correspond with prostate cancer survival.
When the Northern Virginia Regional Health Information Organization (NoVaRHIO) goes live with its first major step towards an full scale interoperable eHealth Information Exchange (eHIE) connecting patients and physicians across the region, it will leverage GE Healthcare as a key infrastructure partner.
Genetic testing for a certain mutation in pediatric patients is valuable in determining a cause for unexplained hearing loss, according to a study in the November 2012 issue of Otolaryngology-Head and Neck Surgery.
› Verified 1 days ago
Legacy Nursing And Rehabilitation Of Morgan City Location: 740 Justa Street, Morgan City, Louisiana 70380 Phone: (985) 384-1726 |